Daewoong Hosts NABOTA Training for Partners From 22 Countries
Daewoong Pharmaceutical brought 40 partner-company personnel from 22 countries to Jeju for a three-day academic program on its botulinum toxin product NABOTA.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Daewoong Pharmaceutical said NABOTA EDGE: Global Academic Program would run from September 3 to 5, 2026, at Parnas Hotel Jeju. The company organized the event as NABOTA's overseas business expands.
The participants are 40 key staff members from partner companies in 22 countries. Daewoong Pharmaceutical said the program is intended to deepen their understanding of the product and brand while strengthening local academic and marketing capabilities.
What the program covers
NABOTA EDGE is an education program for sales and academic personnel responsible for the NABOTA business in their respective markets. Daewoong Pharmaceutical is using the Jeju event to share product, academic, and marketing knowledge across its partner network.
Daewoong Pharmaceutical also aims to help partners apply a consistent brand strategy in local markets and reinforce international cooperation. The shared development is therefore a partner-training initiative tied to overseas business expansion, rather than an announcement of a new treatment result.
Clinical limits and patient context
Rapportian and Medical Today describe the event's dates, location, attendance, and business purpose, but their summaries do not present clinical evidence about effectiveness, side effects, recovery, or patient outcomes. The program announcement should not be read as evidence about how a procedure will affect an individual patient.
Botulinum toxin treatment decisions require individual assessment because individual variation matters. Anyone considering treatment should consult a qualified physician about suitability, expected effects, possible side effects, and recovery considerations.
Questions for a consultation
Patients can ask why a particular botulinum toxin product is being proposed and whether it fits their treatment goal and medical history. They can also ask what information supports the clinician's recommendation.
A consultation should also address who will perform the procedure, what side effects need attention, what recovery guidance applies, and when follow-up may be appropriate. These questions connect a company training announcement to the practical information an individual patient needs before making a decision.
Frequently asked questions
When and where is the NABOTA partner program being held?
Daewoong Pharmaceutical scheduled the program for September 3-5, 2026, at Parnas Hotel Jeju. It is a three-day event for partner-company personnel.
Who is attending the NABOTA training?
The event brings together 40 key personnel from partner companies in 22 countries. They include sales and academic staff responsible for NABOTA in local markets.
Does the program announcement show how well treatment works?
No clinical effectiveness or patient-outcome data appear in the summaries from Rapportian and Medical Today. Consult a qualified physician for an individual assessment of expected effects, side effects, and recovery.
Botulinum toxin consultation checklist
- Why are you recommending this botulinum toxin product for my goal?
- How could my medical history affect whether the procedure is suitable?
- Which possible side effects should I watch for?
- What recovery guidance applies to the procedure being discussed?
- Who will perform the procedure, and what follow-up may be needed?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
